Form 4 for CLDX Celldex Therapeutics, Inc.
Accepted 2025-12-17 00:00:00 ET · period of report 2025-12-15 · accession 0001214504-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-17 | 2025-12-15 | CLDX | PEPIN RONALD | SVP, CBO | M - OptEx | $5.47 | +19.3K | 20.1K | +2,530% | +$105.7K |
| DM | 2025-12-17 | 2025-12-15 | CLDX | PEPIN RONALD | SVP, CBO | M - OptEx | $0.00 | -19.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-15 | M | A | 8,333 | $9.02 | 9,097 | D | — | — | (F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F2) Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
| 2 | Common | Common Stock | 2025-12-15 | M | A | 11,000 | $2.78 | 20,097 | D | — | — | (F2) Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan. |
| 3 | Derivative | Incentive Stock Option (right to buy) | 2025-12-15 | M | D | 8,333 | $0.00 | 5,000 | D | $9.02 · — to 2028-06-13 | 8,333 Common Stock | (F1) On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split. (F3) As of June 13, 2022, the option is fully vested. |
| 4 | Derivative | Incentive Stock Option (right to buy) | 2025-12-15 | M | D | 11,000 | $0.00 | 0 | D | $2.78 · — to 2029-06-19 | 11,000 Common Stock | (F4) As of June 19, 2023, the option is fully vested. |